In the Media

Vidac Pharma - Progress in the fight against cancer

Vidac Pharma celebrated a significant milestone on September 19: The US Patent and Trademark Office (USPTO) has granted the biopharmaceutical company a broad patent that protects the unique mechanisms of its cancer therapies. This protection includes, in particular, the active ingredients VDA-1102 and VDA-1275, which specifically reverse the metabo...

An impressive report done by top analyst Herr Peter Thilo Hasler for Sphene Capital GmbH on Vidac Pharma shows what we already knew: our company is in the right direction and indeed the "buy" recommendation of this highly professional Analyst is a great compliment and confirmation that our focus is on the right path.

Vidac Pharma is the only compa...

Vidac Pharma is one of the biotech shooting stars on the German stock market, with its share price having risen by over 230% in the last six months. The Company is now receiving a reinvestment of EUR 600,000 from shareholders to advance the clinical trials of its cancer drug candidates. Vidac will use the funds to conduct a series of clinical trial...

The British biotech company Vidac Pharma (ISIN GB00BM9XQ619) has reached an important milestone in the development of innovative cancer therapies. The US Patent Office has granted the Company a groundbreaking patent for a completely new therapeutic approach: the treatment aims to normalize the metabolism of cancer cells – an approach that experts r...

This is slowly turning into a long-term story. We have reported on Vidac Pharma plc several times in recent weeks. There has been tremendous interest in the stock recently, and even with a premium of 300% at the peak, there are now further potential buyers. Last week, the price briefly reached EUR 1.30, which seems a bit excessive in such a short t...

Vidac Pharma's stock has been one of the positive surprises of the past few months. Driven by strong newsflow, the share price of the cancer-focused company has more than doubled since its low at the end of May at under EUR 0.18. The current consolidation at around EUR 0.30 offers an interesting entry opportunity, as analysts see the potential for...

Vidac Pharma (ISIN: GB00BM9XQ619), a clinical-stage biopharmaceutical company specializing in the development of a novel class of cancer treatments, has been awarded a patent by the United States Patent and Trademark Office (USPTO). This patent provides comprehensive protection for the mechanism of action underlying the Company's oncology and onco-...

The biopharmaceutical oncology company Vidac Pharma (WKN: A3DTUQ | ISIN: GB00BM9XQ619 | Ticker Symbol: T9G) has reported several successes this year. At the end of March 2024, the company received approval from the Japanese Patent Office for its drug candidate VDA-1275. This compound is being used in the preclinical phase against cancer cells and h...

Those interested in investing in promising biotech small-caps should keep Vidac Pharma on the radar. Despite its manageable size, the Company is already in the clinical development phase. The best-known product, VDA-1275, is the focus of interest according to a specialist article, as this drug candidate for the treatment of solid tumors has achieve...

Vidac Pharma shares have gained over 23% in the past four weeks. Driven by strong study data from the biotech company focused on fighting cancer, analysts even see the potential for multiplication. Such euphoria has been absent at Bayer for some time. However, at least there is positive momentum from the pharmaceuticals division again, which is muc...

Vidac Pharma, a listed company in the clinical development phase, offers an exciting and promising prospect. Vidac Pharma's latest product, VDA-1275, is at the center of interest following a technical report. This innovative drug candidate for the treatment of solid tumors has achieved impressive results in preclinical studies. As a monotherapy, VD...

The new technology being developed by Vidac Pharma, a company founded in 2012 and led by Prof. Max Herzberg, one of the founding fathers of the Israeli life sciences industry, is groundbreaking. Vidac Pharma is researching drugs designed to help cancer patients by reversing the abnormal metabolism of cancer cells, thereby stopping the proliferation...

A mega rally could start here, at least according to analysts who analyzed the recently published results of tests with next-generation drug candidates in human and murine tumour models. According to the analysis, Sphene Capital sees a price target of no less than EUR 4.90 for Vidac Pharma, representing a potential upside of 1,662% from the current...

Among the biotech small-cap stocks, Vidac Pharma has recently made headlines. The British-Israeli company has recently published promising results of its studies with the promising compound VDA-1275 in several mouse and human cellular organoid models of solid tumours in a scientific article. The paper has been submitted for independent peer review...

With around 20 million cancer diagnoses worldwide each year, innovative therapeutic approaches are urgently needed. Companies such as Vidac Pharma are currently developing new ways of treating cancer that could lead to a groundbreaking breakthrough. The reason for this is the discovery of a particular enzyme and its mode of action. At the same time...

We have reported several times on Vidac Pharma plc in recent weeks. The interest in the share is enormous for a penny stock, with over 200,000 shares changing hands at times. The Company has just announced that the US Patent and Trademark Office (USPTO) has issued a notice of allowance for a patent application to protect a group of molecules. These...

The biopharmaceutical company Vidac Pharma, which specializes in developing innovative cancer treatments, has recently achieved a significant milestone. On June 3, the Company was awarded a key patent for its group of molecules by the US Patent and Trademark Office. These molecules can release the enzyme hexokinase-2 (HK2) from the mitochondrial VD...

FinanzNachrichten provides financial news and updates specifically related to Vidac Pharma Holdings PLC. It covers the company's stock performance, recent financial news, market analysis, and any significant corporate announcements. The page serves as a resource for investors and analysts looking to stay informed about Vidac Pharma's financial stat...

Vidac Pharma has not yet broken out of its sideways movement, but this is likely only a matter of time. The London-based biotech company is making good progress in cancer research and has been traded as a takeover candidate, especially since Genmab's billion-dollar acquisition of ProfoundBio. Vidac Pharma's innovative approach has the potential to...

There is hope on the horizon for biotech investors, according to news | financial, even if a rally in the Nasdaq Biotech Index late last year did
not persist in 2024. Tough refinancing conditions have been holding the market back, according to the German website.

But if an interest rate cut materializes over the summer, the outlook would look a lot b...

Since the onset of the COVID-19 pandemic, there has been little movement in the biotech sector. However, after a challenging year in 2023, the sector was at least able to start the new year on a solid footing. The surprising takeover of MorphoSys recently got hearts beating again, as Novartis put a whopping EUR 2.7 billion on the table for the canc...

Oncology is on the brink of a golden era. Driven by an increase in cancer cases and impressive scientific advances, including gene and immunotherapies, a billion-dollar market with immense growth prospects is emerging. The increasing demand for personalized medicines and the rapid development of new forms of therapy through technological progress a...

The biopharmaceutical company Vidac Pharma (WKN: A3DTUQ | ISIN: GB00BM9XQ619 | Ticker symbol: T9G), which is based in Israel and the UK, received notification of approval for its drug candidate VDA-1275 from the Japanese Patent Office at the end of March 2024. This has already shown several promising effects in the preclinical phase and has been us...

UK and Israel-based Vidac Pharma plc (STU: T9G, WKN: A3DTUQ, ISIN: GB00BM9XQ619) is another clinical-stage biopharmaceutical company developing first-in-class oncology and oncodermatology therapies. Its breakthrough new technology, which corrects a common feature of all cancer cells, holds the promise of a fundamentally new way of treating cancer a...